Zeynep Eroglu MD
Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma.
Recent Contributions to PracticeUpdate:
- ASCO 2022: Abstract Recommendations From Dr. Zeynep Eroglu for Advanced Melanoma
- Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients With Advanced Melanoma
- Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
- Nivolumab Plus Ipilimumab or Nivolumab Alone vs Ipilimumab in Patients With Advanced Melanoma
- Safe Anti–PD-1 Therapy Discontinuation in Advanced Melanoma
- FDG-PET Long-Term Outcome Prediction With Anti–PD-1 Therapy
- 2021 Top Story in Advanced Melanoma: The DREAMseq Study
- Outcome of Melanoma Patients With Elevated LDH Treated With First-Line Targeted Therapy or PD-1–Based Immune Checkpoint Inhibition
- First-Line BRAF/MEK Inhibitors vs Anti–PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma
- Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody Alone or With Pembrolizumab in Advanced Solid Tumors